|
WO2008073300A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
|
US9149492B2
(en)
|
2008-10-08 |
2015-10-06 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
|
|
US8802646B2
(en)
|
2008-10-08 |
2014-08-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
|
|
WO2010042292A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Trustees Of Dartmouth College |
Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
|
|
US9388414B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
|
US9388413B2
(en)
|
2008-10-08 |
2016-07-12 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
CN101852805B
(zh)
*
|
2009-03-31 |
2015-04-01 |
浙江大学 |
Angptl3作为卵巢癌的诊断标记物的用途
|
|
CN102753186B
(zh)
*
|
2010-01-08 |
2016-09-14 |
Isis制药公司 |
血管生成素样3表达的调节
|
|
AU2015200969A1
(en)
*
|
2010-01-08 |
2015-03-19 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
EP2672996B1
(en)
|
2011-02-07 |
2018-07-04 |
Aggamin LLC |
Methods and systems for treating or preventing pregnancy-related hypertensive disorders
|
|
US8852592B2
(en)
|
2011-05-10 |
2014-10-07 |
Biocare Medical, Llc |
Systems and methods for anti-PAX8 antibodies
|
|
AR087329A1
(es)
|
2011-06-17 |
2014-03-19 |
Regeneron Pharma |
Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
|
|
EP2723758B1
(en)
*
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
|
SG10201805064SA
(en)
|
2011-06-23 |
2018-07-30 |
Ablynx Nv |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
US10316103B1
(en)
|
2012-03-30 |
2019-06-11 |
Biocare Medical, Llc |
Systems and methods for anti-Uroplakin III antibodies
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
US9540449B2
(en)
|
2012-08-13 |
2017-01-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-PCSK9 antibodies with pH-dependent binding characteristics
|
|
EP2900265B1
(en)
|
2012-09-27 |
2018-05-30 |
Biocare Medical, LLC |
Anti-uroplakin ii antibodies systems and methods
|
|
GB201219487D0
(en)
*
|
2012-10-30 |
2012-12-12 |
Cancer Rec Tech Ltd |
Anti-S100A4 antibody molecules and their uses
|
|
US10429390B2
(en)
|
2012-12-18 |
2019-10-01 |
Biocare Medical, Llc |
Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
|
|
DK2962113T3
(da)
|
2013-02-28 |
2019-07-01 |
Biocare Medical Llc |
Systemer og fremgangsmåder med anti-p40-antistoffer
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
UY35368A
(es)
|
2013-03-08 |
2014-10-31 |
Irm Llc |
Péptidos y composiciones para el tratamiento de daño articular
|
|
MA38369B1
(fr)
|
2013-03-08 |
2018-10-31 |
Novartis Ag |
Peptides et compositions pour le traitement d'une lesion de l'articulation
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
US9816997B2
(en)
|
2013-10-03 |
2017-11-14 |
Biocare Medical, Llc |
Anti-SOX10 antibody systems and methods
|
|
BR112016013514B1
(pt)
*
|
2013-12-13 |
2022-04-19 |
Stora Enso Oyj (Fi) |
Papelão de múltiplas camadas
|
|
PT3087183T
(pt)
*
|
2013-12-24 |
2020-10-08 |
Ionis Pharmaceuticals Inc |
Modulação da expressão da proteína relacionada com angiopoietina 3
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
US10100308B2
(en)
|
2014-05-29 |
2018-10-16 |
Trustees Of Dartmouth College |
Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
|
|
US9527922B2
(en)
*
|
2014-12-31 |
2016-12-27 |
Development Center For Biotechnology |
Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
|
|
CN115927335A
(zh)
|
2015-04-13 |
2023-04-07 |
阿尔尼拉姆医药品有限公司 |
类血管生成素3（ANGPTL3）iRNA组合物及其使用方法
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
MA44234B1
(fr)
*
|
2016-02-17 |
2023-10-31 |
Regeneron Pharma |
Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
|
|
MA43734A
(fr)
|
2016-03-03 |
2018-11-28 |
Regeneron Pharma |
Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
FI3448426T3
(fi)
*
|
2016-04-28 |
2025-07-18 |
Regeneron Pharma |
Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
|
|
CA3042236A1
(en)
|
2016-10-28 |
2018-05-03 |
Washington University |
Anti-apoe antibodies
|
|
CN107085112B
(zh)
*
|
2017-05-10 |
2019-03-19 |
武汉圣润生物科技有限公司 |
一种用于检测白血病的试剂盒
|
|
EP3774916A2
(en)
*
|
2018-04-06 |
2021-02-17 |
Biolegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
TW202027794A
(zh)
|
2018-10-03 |
2020-08-01 |
瑞士商諾華公司 |
血管生成素樣３多肽之持續遞送
|
|
MY195550A
(en)
|
2018-10-29 |
2023-01-31 |
Hoffmann La Roche |
Antibody Formulation
|
|
TWI747098B
(zh)
|
2018-12-21 |
2021-11-21 |
美商美國禮來大藥廠 |
抗angptl3/8複合物抗體及其使用方法
|
|
US12559551B2
(en)
|
2019-05-24 |
2026-02-24 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ANGPTL3 antibodies
|
|
CN112062844B
(zh)
*
|
2019-06-10 |
2022-07-19 |
山东博安生物技术股份有限公司 |
抗angptl3抗体及其用途
|
|
US20220380425A1
(en)
*
|
2019-07-04 |
2022-12-01 |
Cadila Healthcare Limited |
Angptl3 based vaccine for the treatment of liver disease
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
CN110938144B
(zh)
*
|
2019-11-27 |
2022-07-26 |
复旦大学附属儿科医院 |
一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
|
|
CA3166346A1
(en)
*
|
2020-01-22 |
2021-07-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-angptl3 antibody and use thereof
|
|
US20240002479A1
(en)
*
|
2020-11-23 |
2024-01-04 |
The Regents Of The University Of Michigan |
Single-chain antibody against flavivirus ns1 protein
|
|
JP2024508896A
(ja)
|
2021-03-04 |
2024-02-28 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法
|
|
WO2022187353A1
(en)
*
|
2021-03-05 |
2022-09-09 |
Anji Pharmaceuticals Inc. |
Methods and compositions for treating sepsis
|
|
WO2022244845A1
(ja)
*
|
2021-05-19 |
2022-11-24 |
国立大学法人熊本大学 |
脂質異常関連疾患治療薬
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
JP2024525611A
(ja)
*
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
AU2022309238A1
(en)
*
|
2021-07-09 |
2024-01-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP4375298A4
(en)
*
|
2021-07-21 |
2025-02-26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
|
|
CN116284377A
(zh)
*
|
2021-12-21 |
2023-06-23 |
复旦大学 |
抗人血管生成素3纳米抗体及其应用
|
|
IL316249A
(en)
|
2022-05-02 |
2024-12-01 |
Novo Nordisk As |
Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
|
|
CN117447592B
(zh)
*
|
2022-07-26 |
2024-05-28 |
北京东方百泰生物科技股份有限公司 |
一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用
|
|
CN116199779B
(zh)
*
|
2022-12-08 |
2023-08-11 |
北京东方百泰生物科技股份有限公司 |
一种抗lilrb4单克隆抗体、其抗原结合片段及其应用
|
|
WO2024130165A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
|
|
CN119192369A
(zh)
*
|
2023-06-25 |
2024-12-27 |
百奥泰生物制药股份有限公司 |
抗angptl3抗体及其应用
|